469 related articles for article (PubMed ID: 33338652)
1. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
Nagasaka M; Zhu VW; Lim SM; Greco M; Wu F; Ou SI
J Thorac Oncol; 2021 May; 16(5):740-763. PubMed ID: 33338652
[TBL] [Abstract][Full Text] [Related]
2. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
[TBL] [Abstract][Full Text] [Related]
3. Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib.
Wang H; Pan R; Zhang X; Si X; Wang M; Zhang L
Thorac Cancer; 2020 Mar; 11(3):594-602. PubMed ID: 31943845
[TBL] [Abstract][Full Text] [Related]
4. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
Wang S; Cang S; Liu D
J Hematol Oncol; 2016 Apr; 9():34. PubMed ID: 27071706
[TBL] [Abstract][Full Text] [Related]
5. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925
[TBL] [Abstract][Full Text] [Related]
6. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
[TBL] [Abstract][Full Text] [Related]
7. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Pirker R
Curr Opin Oncol; 2016 Mar; 28(2):115-21. PubMed ID: 26720671
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Cho BC; Han JY; Kim SW; Lee KH; Cho EK; Lee YG; Kim DW; Kim JH; Lee GW; Lee JS; Shim BY; Kim JS; Chun SH; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Lee Y; Lee DH; Kang JA; Lee N; Kwon MJ; Espenschied C; Yablonovitch A; Ahn MJ
J Thorac Oncol; 2022 Apr; 17(4):558-567. PubMed ID: 34958928
[TBL] [Abstract][Full Text] [Related]
9. And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.
Lau SCM; Ou SI
J Thorac Oncol; 2022 Oct; 17(10):1144-1154. PubMed ID: 36192074
[No Abstract] [Full Text] [Related]
10. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
Soejima K; Yasuda H; Hirano T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
[TBL] [Abstract][Full Text] [Related]
12. Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.
Chen L; Zhou Y; Gan C; Wang X; Liu Y; Dong C; He R; Yang J
Cancer Invest; 2022 Aug; 40(7):590-603. PubMed ID: 35445633
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.
Lamb YN
Target Oncol; 2021 Sep; 16(5):687-695. PubMed ID: 34564820
[TBL] [Abstract][Full Text] [Related]
15. Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Moik F; Riedl JM; Ay C
Ann Oncol; 2024 Mar; 35(3):327. PubMed ID: 38092622
[No Abstract] [Full Text] [Related]
16. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
Lu S; Wang Q; Zhang G; Dong X; Yang CT; Song Y; Chang GC; Lu Y; Pan H; Chiu CH; Wang Z; Feng J; Zhou J; Xu X; Guo R; Chen J; Yang H; Chen Y; Yu Z; Shiah HS; Wang CC; Yang N; Fang J; Wang P; Wang K; Hu Y; He J; Wang Z; Shi J; Chen S; Wu Q; Sun C; Li C; Wei H; Cheng Y; Su WC; Hsia TC; Cui J; Sun Y; Ou SI; Zhu VW; Chih-Hsin Yang J
J Thorac Oncol; 2022 Mar; 17(3):411-422. PubMed ID: 34801749
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Kogure Y; Tachihara M; Fujimoto D; Yamaguchi K; Hamaguchi N; Okamoto I; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2021 Jul; 22(4):376-380. PubMed ID: 33612406
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
[TBL] [Abstract][Full Text] [Related]
20. Uncommon
Okuma Y; Shimokawa M; Hashimoto K; Mizutani H; Wakui H; Murakami S; Atagi S; Minato K; Seike M; Ohe Y; Kubota K;
Future Oncol; 2022 Feb; 18(5):523-531. PubMed ID: 35034503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
